Renaissance Technologies LLC sells 968,039 shares of AstraZeneca PLC (NASDAQ:AZN) stock

Renaissance Technologies LLC sells 968,039 shares of AstraZeneca PLC (NASDAQ:AZN) stock

Renaissance Technologies LLC reduced its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) stock by 43.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,241,963 shares of the company’s shares after selling 968,039 shares during the period. Renaissance Technologies LLC’s holdings in AstraZeneca were valued at $88,887,000 at the end of the fourth quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. ICA Group Wealth Management LLC purchased a new stake in AstraZeneca in the fourth quarter worth $26,000. Parkside Financial Bank & Trust raised its stake in AstraZeneca by 4,875.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after acquiring an additional 390 shares during the period. Purchased by Fairfield Bush & CO. New stake in AstraZeneca in Q1 worth $28,000. Sunbelt Securities Inc. bought New stake in AstraZeneca in Q1 worth $33,000. Finally, Archer Investment Corp raised its stake in AstraZeneca by 137.0% in the 2nd quarter. Archer Investment Corp. now owns 474 shares of the company’s stock worth $34,000 after acquiring an additional 274 shares during the period. Institutional investors own 15.68% of the company’s shares.

Analysts set new price targets

AZN has been the subject of a number of research analyst reports. StockNews.com began coverage of AstraZeneca in a research note on Thursday, October 5th. They issued a “strong buy” rating for the stock. Jefferies Financial Group raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Monday, September 25. Finally, Erste Group Bank reaffirmed a “hold” rating on AstraZeneca shares in a report on Friday, September 8th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca has a “Moderate Buy” consensus rating and a consensus target price of $103.00.

Get our latest report on AstraZeneca

AstraZeneca stock performance

NASDAQ AZN shares opened at $64.59 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 0.79 and a quick ratio of 0.60. The stock’s fifty day moving average price is $65.18 and its two-hundred day moving average price is $68.42. AstraZeneca PLC has a one-year low of $61.73 and a one-year high of $76.56. The company has a market cap of $200.22 billion, a P/E ratio of 33.99, a P/E ratio of 1.28 and a beta of 0.51.

AstraZeneca (NASDAQ:AZN – Get Free Report) last released its earnings results on Wednesday, November 8th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.03. The company’s revenues for the quarter amounted to $11.49 billion, compared to analyst estimates of $11.55 billion. AstraZeneca had a return on equity of 30.30% and a net margin of 13.10%. AstraZeneca’s quarterly revenue rose 4.6% year over year. During the same period a year earlier, the company posted $0.84 EPS. On average, equity analysts expect AstraZeneca PLC to post 3.64 earnings per share for the current year.

About AstraZeneca

(Free report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing and commercialization of prescription drugs. The Company’s marketed products include Calquince, Enherto, Faslodex, Imfinzi, Irisa, Coselogo, Lomoxeti, Lynparza, Orbatis, Tagrisso, and Zoladex oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril Cardiovascular, kidney and metabolism. Acolyte, Acolyte, Vanticon, Bevesby Aerosphere, Breastry Aerosphere, Bricanyl Resulz, Turbuhaler, Dalirsp/Daxas, Duacler Genaware, Fasenra, Pulmicort, Rhinocort, Savnilo, Symbicort, and Tezespir for respiratory and immune diseases; Canoma, Soliris, Strensic, and Oltomiris for rare diseases.

See also

Institutional Ownership QoQ for AstraZeneca (NASDAQ:AZN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team before publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider using AstraZeneca, you’ll want to hear this.

MarketBeat tracks the highest-rated and best-performing research analysts on Wall Street and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly whispering to clients to buy now before the broader market catches up… and AstraZeneca wasn’t on the list.

While AstraZeneca currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View the five stocks here

7 stocks to buy and hold forever

Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlook is so promising.

Get this free report

    (Tags for translation)AstraZeneca

You may also like...

Leave a Reply